Here's what we'll cover
Here's what we'll cover
Why GLP-1 Use Has Exploded Across the Country
If it feels like everyone you know is talking about Ozempic or Wegovy, that's because prescription rates really have surged. GLP-1 medication use in the U.S. has nearly quadrupled over just a two-year span, a shift that represents one of the fastest adoption curves in modern pharmaceutical history.
GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces to regulate blood sugar and appetite. GLP-1 receptor agonists mimic this hormone. Originally approved for type 2 diabetes, these medications have since earned FDA approval for chronic weight management, driving a dramatic expansion of who is being prescribed them.
This isn't a trend driven by one medication or one patient population. It spans age groups, income levels, and medical histories, and it's reshaping how primary care physicians, endocrinologists, and telehealth providers approach both obesity and metabolic disease.
Which Medications Are Driving the Numbers
Two drug classes are responsible for most of the growth: semaglutide-based medications and tirzepatide-based medications.
Semaglutide is the active ingredient in Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). It works by activating GLP-1 receptors in the brain and gut, reducing appetite and slowing how quickly food leaves your stomach.
Tirzepatide is the active ingredient in Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight loss). It works on both GLP-1 and GIP receptors, a dual mechanism that clinical trials have shown can produce greater average weight loss than semaglutide alone.
Prices vary by pharmacy, location, and whether you use manufacturer savings programs or third-party coupons.
What Rapid Adoption Means for Drug Supply and Availability
When demand quadruples in two years, supply chains feel the pressure. That's exactly what happened with semaglutide. The FDA placed both Ozempic and Wegovy on its drug shortage list at various points during the surge, which opened a window for compounding pharmacies to legally produce copies of the medication.
Compounded semaglutide became widely available through telehealth platforms during the shortage period. However, the FDA has since moved to take compounded semaglutide off the shortage list, which has legal and practical implications for compounding pharmacies and the patients using their products.
If you're currently using a compounded version of semaglutide, it's important to talk to your provider about your options. The regulatory landscape is shifting, and what's available today may change in the coming months.
Tirzepatide has also faced intermittent supply constraints, though its shortage status has varied by dose and region.
How This Surge Is Affecting What You Pay
More patients competing for the same drugs generally means higher demand on insurance plans, which has led to mixed results for coverage.
Some commercial insurers have expanded GLP-1 coverage, especially for patients with a documented obesity-related condition. Others have tightened prior authorization requirements, making it harder to get the drug approved even when a physician recommends it.
Medicare Part D began covering Wegovy for patients with cardiovascular disease in 2024, following trial data showing reduced risk of serious cardiovascular events. That was a meaningful policy shift, but coverage gaps remain significant for many patients.
Out-of-pocket costs without insurance remain steep, often exceeding $1,000 per month for brand-name medications. If you're paying full price, there are legitimate ways to reduce that burden.
- Manufacturer savings cards (Novo Nordisk offers one for Wegovy; Eli Lilly offers one for Zepbound) can reduce costs substantially for eligible commercially insured patients.
- Telehealth platforms that prescribe compounded semaglutide or tirzepatide often charge significantly less per month, though the regulatory environment is changing.
- Third-party coupons and pharmacy discount programs can help if you're uninsured or your insurance doesn't cover these medications.
You can compare current savings options through our GLP-1 Coupons page.
The Rise of Telehealth GLP-1 Prescribing
One major factor behind the quadrupling of GLP-1 use is the explosion of telehealth platforms that can prescribe these medications entirely online. Before the pandemic, getting a GLP-1 prescription typically required an in-person visit with an endocrinologist or weight management specialist. That barrier has largely fallen.
Today, you can complete a health questionnaire, have an asynchronous review by a licensed clinician, and receive a prescription within 24 to 48 hours in many cases. That convenience has brought GLP-1 medications to patients who might never have sought traditional obesity treatment.
But convenience comes with trade-offs. Not all telehealth platforms offering GLP-1 prescriptions provide the same level of clinical oversight, follow-up, or support. Some offer comprehensive programs with regular check-ins, nutrition guidance, and dose adjustments. Others are closer to prescription-only services with minimal ongoing support.
What to Look for in a GLP-1 Provider
- Is a licensed clinician reviewing your health history and not just a questionnaire algorithm?
- Will you have access to follow-up appointments for side effect management and dose escalation?
- Is the platform transparent about whether it's prescribing brand-name or compounded medication?
- What happens if you have a serious side effect or need a dosage change?
Comparing providers on these criteria matters more than comparing monthly prices alone. You can review vetted options through our Best Providers page.
Who Is Actually Getting Prescribed GLP-1s Now
The patient profile for GLP-1 medications has broadened considerably. Early adoption was concentrated among patients with type 2 diabetes who were already in the healthcare system and familiar with injectable medications. The current wave looks very different.
GLP-1 prescriptions are now common among:
- Adults with obesity (BMI of 30 or higher) who do not have diabetes
- Adults who are overweight (BMI of 27 or higher) with at least one weight-related condition such as high blood pressure, sleep apnea, or high cholesterol
- Patients with cardiovascular disease who may benefit from semaglutide's documented heart-protective effects
- Younger adults using telehealth platforms who might not have engaged with traditional weight management programs
This broadening of the patient base is part of what's driving the numbers up so sharply. It also reflects a slow but meaningful shift in how the medical community classifies and treats obesity, increasingly recognizing it as a chronic metabolic disease rather than a lifestyle issue.
The Compounded Medication Question
No discussion of America's GLP-1 surge is complete without addressing compounded semaglutide and tirzepatide. Compounded medications are custom-prepared drugs made by licensed compounding pharmacies, typically when an FDA-approved drug is in shortage or a patient needs a specific formulation.
During the peak of the semaglutide shortage, many patients turned to compounded versions, often at a fraction of the brand-name cost. Some telehealth platforms built their entire business model around connecting patients with these compounded formulations.
The FDA's decision to remove semaglutide from the shortage list means that most compounding pharmacies can no longer legally prepare copies of the drug for general distribution. Some pharmacies are challenging this decision. The situation is still evolving.
If you're using compounded semaglutide, the key questions to ask your provider include:
- Is this pharmacy operating within current FDA guidelines?
- What is the source and quality of the active pharmaceutical ingredient?
- What is my plan if compounded versions become unavailable in my area?
Compounded tirzepatide is in a similar but slightly different position, with its shortage status and regulatory future still being determined.
Questions to Ask Your Doctor Before Starting a GLP-1
If you're considering a GLP-1 medication for the first time, the surge in prescribing doesn't mean you should rush a decision. These are serious medications with real benefits and real side effects, and the right choice depends on your individual health picture.
Here are specific questions worth raising with your provider:
- Am I a candidate for a GLP-1 based on my current BMI and health conditions?
- Which medication is most appropriate for me, and why?
- What dose will I start at, and how will we escalate over time?
- What side effects should I watch for, especially in the first few weeks?
- How will we measure whether this medication is working for me?
- What does my insurance cover, and what will I actually pay each month?
- Is there a lifestyle or nutrition component to this treatment that I should be following?
Getting clear answers to these questions before you start will help you set realistic expectations and stay on track.
No waiting list. No insurance needed.
Frequently Asked Questions
Why has GLP-1 medication use increased so dramatically in the U.S.?
Several factors drove the surge: FDA approvals for chronic weight management, high-profile media coverage, the expansion of telehealth prescribing, and strong clinical evidence for meaningful weight loss. Patients who previously had limited options for medically supervised weight loss now have accessible, effective treatments.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide, but they are approved for different purposes. Ozempic is FDA-approved for type 2 diabetes management, while Wegovy is FDA-approved for chronic weight management in adults with obesity or overweight with a related health condition. Wegovy also uses a higher maximum dose than Ozempic.
Is compounded semaglutide still legal to prescribe?
The regulatory situation is evolving. The FDA removed semaglutide from its drug shortage list, which limits the ability of most compounding pharmacies to legally prepare copies for general distribution. Patients currently using compounded semaglutide should consult their provider about their options and any changes to their supply.
Does insurance cover GLP-1 medications for weight loss?
Coverage varies widely by insurer and plan. Some commercial plans cover GLP-1s for obesity when specific criteria are met. Medicare Part D began covering Wegovy for patients with cardiovascular disease in 2024. Many plans still require prior authorization, and some do not cover weight loss drugs at all. Always verify with your insurer before starting.
How much do GLP-1 medications cost without insurance?
Brand-name GLP-1 medications typically cost between $900 and $1,400 per month without insurance. Manufacturer savings cards can significantly reduce costs for eligible commercially insured patients. Compounded versions have been available at lower prices, though their regulatory status is changing.
What is tirzepatide and how does it differ from semaglutide?
Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1 and GIP receptor agonist, meaning it activates two different hormone pathways. Clinical trials have shown it can produce greater average weight loss than semaglutide in head-to-head comparisons, though individual responses vary. Your provider can help determine which is more appropriate for your situation.
What This Surge Means for You Specifically
America's GLP-1 boom is genuinely significant news, but the number that matters most to you isn't the national prescription count. It's whether you're getting the right medication, at a dose that works, from a provider who is actually monitoring your progress, at a price you can sustain.
The rapid growth of this market has created real opportunities. More providers, more competition, and more awareness have made GLP-1 medications more accessible than they were two years ago. It's easier to get a prescription, find savings programs, and compare your options.
But growth has also created noise. Not every telehealth platform offering GLP-1s provides the same standard of care. Not every compounded product carries the same quality assurance. And not every patient who wants a GLP-1 is getting proper education about what to expect, how to manage side effects, or what lifestyle factors will determine their long-term results.
The Patients Getting the Best Outcomes
Across the clinical literature and real-world data, the patients who do best on GLP-1 medications share a few common traits. They work with providers who monitor their labs, weight, and side effects regularly. They understand the medication is a tool, not a standalone solution. And they have realistic expectations about the pace of weight loss and what happens if they stop taking the drug.
If you don't have that kind of support yet, that's worth prioritizing as much as finding the best price.
The Bottom Line
The quadrupling of GLP-1 use in the U.S. reflects something real: these medications work for many people, and the medical community is increasingly willing to prescribe them. But a larger market means more decisions you need to make as a patient, not fewer.
You'll need to navigate insurance coverage, evaluate provider quality, understand the difference between brand-name and compounded options, and ask the right questions before you start. None of that is overwhelming, but it does require some homework.
GLP-1.com exists to make that homework easier. Whether you're just starting your research or already on a medication and trying to reduce your costs, you'll find tools here to help.
- Compare top GLP-1 providers side by side to find one that fits your needs and budget.
- Explore current GLP-1 coupons and savings programs that may significantly reduce what you pay each month.
- Learn more about specific medications like Ozempic, Wegovy, and Mounjaro to understand what differentiates them.
As always, consult with your physician or a qualified healthcare provider before starting, switching, or stopping any GLP-1 medication. The information here is designed to help you have better, more informed conversations with your care team, not to replace those conversations.